Plaque busters: strategies to inhibit amyloid formation in Alzheimer's disease.
about
New Class of Inhibitors of Amyloid-beta Fibril Formation. IMPLICATIONS FOR THE MECHANISM OF PATHOGENESIS IN ALZHEIMER'S DISEASEContribution by synaptic zinc to the gender-disparate plaque formation in human Swedish mutant APP transgenic miceA chemical analog of curcumin as an improved inhibitor of amyloid Abeta oligomerizationPurification and Characterization of Recombinant N-Terminally Pyroglutamate-Modified Amyloid-β Variants and Structural Analysis by Solution NMR SpectroscopySimultaneous monitoring of peptide aggregate distributions, structure, and kinetics using amide hydrogen exchange: application to Abeta(1-40) fibrillogenesisCharacterization of intermolecular beta-sheet peptides by mass spectrometry and hydrogen isotope exchange.Inhibition of fibril formation of Abeta by guanidiniocarbonyl pyrrole receptors.Amyloid-beta associated with chitosan nano-carrier has favorable immunogenicity and permeates the BBB.Quantitative structure-activity relationship analysis of β-amyloid aggregation inhibitors.A liposome-based therapeutic vaccine against beta -amyloid plaques on the pancreas of transgenic NORBA mice.Feasibility of β-sheet breaker peptide-H102 treatment for Alzheimer's disease based on β-amyloid hypothesis.Alzheimer disease therapy: can the amyloid cascade be halted?Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice.The molecular mechanisms of the anti-amyloid effects of phenols.A survey of peptides with effective therapeutic potential in Alzheimer's disease rodent models or in human clinical studies.Therapeutic strategies against protein misfolding in neurodegenerative diseases.Nanotechnology-based drug delivery systems for targeting, imaging and diagnosis of neurodegenerative diseases.Pharmacological models in Alzheimer's disease researchInhibition of amyloid peptide fragment Aβ25-35 fibrillogenesis and toxicity by N-terminal β-amino acid-containing esapeptides: is taurine moiety essential for in vivo effects?Computational and experimental studies on β-sheet breakers targeting Aβ1-40 fibrils.Effects of oligomerization and secondary structure on the surface behavior of pulmonary surfactant proteins SP-B and SP-C.Aβ1-25-Derived Sphingolipid-Domain Tracer Peptide SBD Interacts with Membrane Ganglioside Clusters via a Coil-Helix-Coil Motif.Prevention of Alzheimer's disease-associated Abeta aggregation by rationally designed nonpeptidic beta-sheet ligands.Inhibition of HEWL fibril formation by taxifolin: Mechanism of action.Pharmacological profiles of peptide drug candidates for the treatment of Alzheimer's disease.Pharmacokinetic Properties of a Novel D-Peptide Developed to be Therapeutically Active Against Toxic β-Amyloid Oligomers.Amyloid formation modulates the biological activity of a bacterial protein.Transport characteristics of a beta sheet breaker peptide across excised bovine nasal mucosa.Use of curcumin in diagnosis, prevention, and treatment of Alzheimer's disease.Hypothetical structure of human serum amyloid A protein
P2860
Q22248067-0DE01D4B-CE47-462E-811E-7EC2554E4D94Q24530682-48BD7AF3-9674-4F69-81B3-699E3EA93083Q28481562-BDC13648-33F0-40E1-8A91-CC62AE800D73Q28550062-F4702ED3-6CDE-416D-BABD-2366C2B023B0Q30438164-C5E356EE-0CC9-4921-BA00-390E6809077DQ30882523-AFD7F467-B02D-458A-9711-25154BFC1B85Q31148363-E918004A-BF49-49CD-9C1B-964B26532955Q33573458-688A348F-E504-4920-AFAF-C670C8A29664Q33774384-A030C64E-1F11-4887-BE09-F898A35315D3Q34013221-DF2D4BE5-ABF7-454F-B724-717D4BB54E68Q34457296-56372AC4-D5F5-4170-965A-442934BC37D2Q34828328-7B1B34EB-3736-4F5D-B4C3-5FBEE2201E42Q35834451-C26FD7F9-35C9-4751-BDE5-A5C52C6492A7Q36799375-0379E045-57C0-4FC9-AEAB-C9045D60F667Q37981246-2525954D-5D4E-4C97-886D-1E29571700BFQ38088318-E3BF977C-E599-42A0-AA3A-66BCAD612D03Q38130176-34BD6A86-D3F6-47DD-9B7A-94B81DF7E1DDQ38578433-950EC96A-F0AF-41B0-8EEB-A0B6515C883AQ39458829-EEAA6A58-58A6-47F1-9F4B-ABA860441CF7Q39997860-0CED0A0F-9855-4385-8941-C9750AC4983FQ40232091-CC8AD4D6-0F0B-468F-9AE4-D634BA30C14CQ42058605-B7DC867E-155B-4FDF-9EA8-D4D580955E71Q45025078-136992CA-89F9-446C-99B8-0BA2CD24C976Q46262746-08195DFA-D0D4-4A03-977F-0CD992CD3FFDQ48391151-774A1B13-DD06-466E-85BF-4AA3954EF337Q52149113-5AEA1F54-E26E-4AD4-B6E5-D3EC4A92566AQ53371124-047770D7-4DE0-49C7-A8BA-B3678AD7B204Q53383867-278C3947-6C4F-4AC5-9A7B-8A2B74982A6FQ53397811-9ECF9886-B827-4F78-8B7B-F97D7A20876CQ58174681-7106765D-8BD3-4298-B481-975C3549476F
P2860
Plaque busters: strategies to inhibit amyloid formation in Alzheimer's disease.
description
1999 nî lūn-bûn
@nan
1999 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Plaque busters: strategies to inhibit amyloid formation in Alzheimer's disease.
@ast
Plaque busters: strategies to inhibit amyloid formation in Alzheimer's disease.
@en
type
label
Plaque busters: strategies to inhibit amyloid formation in Alzheimer's disease.
@ast
Plaque busters: strategies to inhibit amyloid formation in Alzheimer's disease.
@en
prefLabel
Plaque busters: strategies to inhibit amyloid formation in Alzheimer's disease.
@ast
Plaque busters: strategies to inhibit amyloid formation in Alzheimer's disease.
@en
P1476
Plaque busters: strategies to inhibit amyloid formation in Alzheimer's disease.
@en
P2093
P304
P356
10.1016/S1357-4310(99)01508-7
P577
1999-08-01T00:00:00Z